Values First Advisors’s Royalty Pharma RPRX Stock Holding History

Values First Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.21M	Sell	20,673 -332	-2%	-$19.6K	0.57%	55
2026 Q2	$1.18M	Buy	21,005 +234	+1%	+$12.2K	0.54%	58
2026 Q1	$996K	Buy	20,771 +565	+3%	+$24.7K	0.52%	58
2025 Q4	$781K	Buy	20,206 +3,122	+18%	+$119K	0.41%	76
2025 Q3	$603K	Buy	17,084 +1,721	+11%	+$62.3K	0.32%	86
2025 Q2	$554K	Sell	15,363 -170	-1%	-$5.63K	0.3%	96
2025 Q1	$484K	Sell	15,533 -430	-3%	-$13.6K	0.28%	97
2024 Q4	$407K	Buy	15,963 +5,551	+53%	+$147K	0.22%	110
2024 Q3	$295K	Buy	10,412 +738	+8%	+$20.4K	0.16%	126
2024 Q2	$255K	Sell	9,674 -88	-0.9%	-$2.44K	0.15%	140
2024 Q1	$296K	Buy	+9,762	New	+$288K	0.17%	134
2023 Q4	–	Sell	-8,811	Closed	-$239K	–	176
2023 Q3	$239K	Buy	+8,811	New	+$262K	0.15%	132
2023 Q2	–	Sell	-5,303	Closed	-$191K	–	304
2023 Q1	$191K	Buy	+5,303	New	+$197K	0.12%	141

Other funds holding RPRX

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Todd Asset Management Louisville, Kentucky $5.51B AUM 33.77% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return

Kepler Cheuvreux Nyon $1.65B AUM 36.86% 1-Year Est. Return

Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return

Values First Advisors's RPRX Position: Q3 2026 in Review

Values First Advisors reduced its Royalty Pharma (RPRX) stake by 1.6% in Q3 2026, selling an estimated $19.6K and leaving 20,673 shares worth $1.21M. The position accounts for 0.57% of the portfolio, ranked #55.

Values First Advisors first reported a position in RPRX in Q1 2023 and has held it in 13 quarters since. 179 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

Values First Advisors held 20,673 shares of Royalty Pharma worth $1.21M as of Q3 2026.
Values First Advisors sold 332 Royalty Pharma shares in Q3 2026, an estimated $19.6K.
Royalty Pharma made up 0.57% of Values First Advisors's portfolio in Q3 2026, its #55 holding.
Values First Advisors first reported a position in Royalty Pharma in Q1 2023 and has held it in 13 quarters since.
179 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Values First Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.